Tumors treated with MRTX849 + anti–PD-1 showed a similar architecture to the MRTX849 monotherapy group, except for the increased Treg presence in the local T cell/DC aggregates at the tumor interface (Fig. 8E). The gene discussed is PDCD1; the disease is neoplasm.